SCHEMBL3489075

SCHEMBL3489075

Nc1cc(Cl)cc(Cl)c1S(=O)(=O)NCc1ccc(Cl)cc1

nearest known ligand 0.52

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.52
MEN1 O00255 4/20 0.51
KMT2A Q03164 4/20 0.51
CYP19A1 P11511 1/20 0.47
MAPK1 P28482 1/20 0.46
HSD17B10 Q99714 1/20 0.46
LMNA P02545 2/20 0.43
KDM4E B2RXH2 1/20 0.43
POLB P06746 2/20 0.42
CA1 P00915 2/20 0.42
CA2 P00918 2/20 0.42
CA9 Q16790 1/20 0.42
NR3C1 P04150 2/20 0.41
NR3C2 P08235 2/20 0.41
MCL1 Q07820 1/20 0.41
PGR P06401 1/20 0.41
SLC12A2 P55011 1/20 0.40
SLC12A5 Q9H2X9 1/20 0.40
CNR1 P21554 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3489110 0.92 ALDH1A1 (0.44) ALDH1A1MEN1KMT2ACYP19A1MAPK1
SCHEMBL3489635 0.90 CYP19A1 (0.43) ALDH1A1MEN1KMT2ACYP19A1LMNA
SCHEMBL3488631 0.90 KMT2A (0.52) ALDH1A1MEN1KMT2ACYP19A1LMNA
SCHEMBL3488618 0.90 NSD2 (0.50) ALDH1A1MEN1KMT2ACYP19A1LMNA
SCHEMBL3491178 0.90 LMNA (0.52) ALDH1A1MEN1KMT2ACYP19A1LMNA
SCHEMBL9275311 0.88 TP53 (0.41) ALDH1A1MEN1KMT2ACYP19A1LMNA
SCHEMBL3491921 0.87 SMN1; SMN2 (0.53) ALDH1A1KMT2ALMNA
SCHEMBL3490641 0.87 LMNA (0.52) ALDH1A1CYP19A1LMNACNR1
SCHEMBL9218252 0.87 NSD2 (0.52) ALDH1A1MEN1KMT2ACYP19A1CA1
SCHEMBL3490497 0.87 CYP19A1 (0.55) ALDH1A1MEN1KMT2ACYP19A1CA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100035866-A1 NOVEL SUBSTITUTED-1, 1-DIOXO-BENZO[1,2,4]THIADIAZIN-3ONES, PREPARATION METHOD THEREOF, AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) 2010-02-11 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100035866-A1 NOVEL SUBSTITUTED-1, 1-DIOXO-BENZO[1,2,4]THIADIAZIN-3ONES, PREPARATION METHOD THEREOF, AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME OPRD1, HTR6, HTR1D ALDH1A1 2748/4885MEN1 4200/4885KMT2A 4557/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.